# Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592) in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-120)

> **NCT03336502** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 70 (actual)

## Conditions studied

- Fungal Infection

## Interventions

- **DRUG:** Posaconazole

## Key facts

- **NCT ID:** NCT03336502
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-20
- **Primary completion:** 2018-11-26
- **Final completion:** 2018-11-26
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2019-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03336502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03336502, "Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592) in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-120)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03336502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*